BRISTOL-MYERS SQUIBB COMPANY Line of Credit Facility, Maximum Borrowing Capacity
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Line of Credit Facility, Maximum Borrowing Capacity of $6.00 billion as of 2021-12-31, per its 10-Q filed 2022-10-26.
Discontinued › Notes › Debt
us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity · last filed 2022-10-26
- 2021-12-31: Line of Credit Facility, Maximum Borrowing Capacity $6.00B.
- 2021-09-30: Line of Credit Facility, Maximum Borrowing Capacity $6.00B.
- 2021-06-30: Line of Credit Facility, Maximum Borrowing Capacity $6.00B.
- 2021-03-31: Line of Credit Facility, Maximum Borrowing Capacity $6.00B.
| Period end | Line of Credit Facility, Maximum Borrowing Capacity | Line of Credit Facility, Maximum Borrowing Capacity as first filed |
|---|---|---|
| 2021-12-31 | $6.00B 10-Q · filed 2022-10-26 | |
| 2021-09-30 | $6.00B 10-Q · filed 2021-10-27 | |
| 2021-06-30 | $6.00B 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $6.00B 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $6.00B 10-K · filed 2021-02-10 | |
| 2019-12-31 | $6.00B 10-K · filed 2020-02-24 | |
| 2018-12-31 | $5.00B 10-K · filed 2019-02-25 | |
| 2017-12-31 | $5.00B 10-K · filed 2018-02-13 | |
| 2012-12-31 | $1.50B 10-K · filed 2013-02-15 | |
| 2011-12-31 | $2.00B 10-K · filed 2012-02-17 | |
| 2011-09-30 | $1.50B 10-Q · filed 2011-10-27 | |
| 2010-12-31 | $1.50B 10-K · filed 2012-02-17 | $2.00B 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |